A multi-disciplinary brain tumor board meets on a weekly basis so patient care management benefits from input from specialists in radiation oncology, medical oncology , neuropathology, neurosurgery, and neurology. Bradykinin analog that temporarily increases permeability of the BBTB to allow better delivery of antitumor agents. I protocol in recurrent brain tumors show surprising responses to treatments in recurrent malignant glioma. Phase I trial with IA carboplatin for metastatic brain tumors. Phase I study using TGF-B antisense vaccine gene therapy in newly diagnosed glioblastoma multiforme.
Gancyclovir delivery provides for cell kill selecting for transfected cells.
Basic research is underway regarding the use of molecular approaches to define the most effective micro environment for the durable formation of immune response. Advances in cytokine gene therapy and dendritic cell therapy are being exploited for this research. Research Basic research is being conducted to define new methods of improving antitumor agent delivery to malignant brain tumors. Translational Gene Expression Research Use of gene array screening the differential gene expression of up to 5000 genes on individual patient's glioma mRNA in an attempt to better clarify prognosis and response to treatment. This approach will provide improved individualized treatment which should translate into effective therapeutic choices providing improved responses and prognostic information.